More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a ...

CURE partnered with SHARE Cancer Support to learn more about the importance of emotional well-being and a strong support ...

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved ...

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other ...